HomeCompareNBGIF vs PFE

NBGIF vs PFE: Dividend Comparison 2026

NBGIF yields 4.76% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.2K in total portfolio value· pulled ahead in Year 9
10 years
NBGIF
NBGIF
● Live price
4.76%
Share price
$16.02
Annual div
$0.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.3K
Annual income
$645.85
Full NBGIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NBGIF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBGIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBGIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NBGIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBGIF
Annual income on $10K today (after 15% tax)
$404.73/yr
After 10yr DRIP, annual income (after tax)
$548.97/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,770.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBGIF + PFE for your $10,000?

NBGIF: 50%PFE: 50%
100% PFE50/50100% NBGIF
Portfolio after 10yr
$38.4K
Annual income
$13,452.29/yr
Blended yield
34.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NBGIF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBGIF buys
0
PFE buys
0
No recent congressional trades found for NBGIF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBGIFPFE
Forward yield4.76%6.13%
Annual dividend / share$0.76$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$27.3K$49.6K
Annual income after 10y$645.85$26,258.71
Total dividends collected$5.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: NBGIF vs PFE ($10,000, DRIP)

YearNBGIF PortfolioNBGIF Income/yrPFE PortfolioPFE Income/yrGap
1$11,176$476.15$9,153$693.39+$2.0KNBGIF
2$12,456$497.34$8,593$849.25+$3.9KNBGIF
3$13,846$518.02$8,336$1,066.78+$5.5KNBGIF
4$15,353$538.16$8,437$1,384.80+$6.9KNBGIF
5$16,986$557.70$9,013$1,875.40+$8.0KNBGIF
6$18,751$576.64$10,306$2,680.72+$8.4KNBGIF
7$20,659$594.93$12,820$4,101.38+$7.8KNBGIF
8$22,717$612.57$17,673$6,826.70+$5.0KNBGIF
9← crossover$24,937$629.55$27,543$12,591.86$2.6KPFE
10$27,329$645.85$49,560$26,258.71$22.2KPFE

NBGIF vs PFE: Complete Analysis 2026

NBGIFStock

National Bank of Greece S.A., together with its subsidiaries, provides financial products and services in Greece, the United Kingdom, North Macedonia, Romania, Cyprus, Bulgaria, Malta, Egypt, and Luxembourg. The company operates through Retail Banking, Corporate & Investment Banking, Trouble Assets Unit, Global Markets and Asset Management, Insurance, International Banking Operations, and Other segments. The Retail Banking segment provides deposit, investment, bancassurance products, mortgage loans, consumer and small business lending, debit and credit cards, prepaid cards, and other traditional products and services for individual customers, professionals, and small-medium and small sized companies through its network of branches and digital businesses. The Corporate & Investment Banking segment offers financial and investment advisory services, deposit accounts, loans, foreign exchange, and trade services for corporate customers; and lending services for large and medium-sized companies, as well as shipping finance services. The Trouble Assets Unit segment manages various loans. The Global Markets and Asset Management segment is involved in treasury activities; and provision of asset management, custody, private equity, and brokerage services. The Insurance offers various insurance products. The International Banking Operations segment offers traditional commercial banking, such as commercial and retail credit, trade financing, foreign exchange, and deposits; shipping finance; investment banking; and brokerage services through its foreign branches. The Other segment engages in the real estate management and warehousing businesses. As of December 31, 2021, the company operates 337 branches, 16 Transaction Offices, 2 I-Bank Stores, and 1,474 ATMs in Greece. National Bank of Greece S.A. was founded in 1841 and is headquartered in Athens, Greece.

Full NBGIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NBGIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBGIF vs SCHDNBGIF vs JEPINBGIF vs ONBGIF vs KONBGIF vs MAINNBGIF vs JNJNBGIF vs MRKNBGIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.